Key facts
- Novo Nordisk is partnering with AI company Anthropic.
- The collaboration aims to accelerate the development of new medicines and AI-driven software.
- Novo Nordisk will use Anthropic's AI models, including Claude Science, to advance its research.
- Novo Nordisk aims to become the world's most AI-driven healthcare company.
- Anthropic CEO Dario Amodei stated that using frontier AI models could shorten research timelines.
Danish pharmaceutical giant Novo Nordisk announced a significant collaboration with AI firm Anthropic on September 16, 2026, to accelerate the development of new medicines and AI-driven software. The partnership intends to leverage Anthropic's advanced AI models, including Claude Science, to enhance Novo Nordisk's research and development efforts, with the company aiming to become the world's most AI-driven healthcare company.
Novo Nordisk CEO Mike Doustdar stated that the collaboration will "supercharge our R&D organisation" and help bring new health solutions to patients with chronic diseases. He also noted that AI tools offer "completely new scientific opportunities" for understanding human biology and drug mechanics. Anthropic CEO Dario Amodei suggested that the increasing capabilities of AI could compress a century's worth of biological and medical breakthroughs into a decade, emphasizing that the partnership will include "robust data governance and human oversight."
The announcement follows European Commission President Ursula von der Leyen's recent remarks on the benefits of AI in healthcare, including its potential for early cancer detection. Despite broader concerns about AI's existential risks, Novo Nordisk appears undeterred in its pursuit of AI integration.